Login to Your Account



Fed Circuit delivers mixed bag on PCSK9 claims, vacates injunction

By Mari Serebrov
Regulatory Editor

Friday, October 6, 2017

In a precedent-setting decision Thursday, the U.S. Court of Appeals for the Federal Circuit granted Sanofi SA and Regeneron Pharmaceuticals Inc. a do-over of sorts on whether their cholesterol drug Praluent infringes Amgen Inc.'s patent claims for antibodies targeting PCSK9.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription